speb/financial-data huggingface dataset:
NURECA.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 1931100000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 2700000.00
NURECA.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 610600000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Current Assets: 1925920000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 5530000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Current Debt: 1580000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 7110000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Current Deferred Taxes Liabilities: 8360000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 92730000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 1680000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Depreciation: 20460000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 23620000.00
NURECA.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 23620000.00
NURECA.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 20460000.00
NURECA.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 10000175.00
NURECA.NS income_statement (annual, 2024-03-31) — Diluted EPS: -1.79
NURECA.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: -17940000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 120000.00
NURECA.NS income_statement (annual, 2024-03-31) — EBIT: -22260000.00
NURECA.NS income_statement (annual, 2024-03-31) — EBITDA: 1360000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: -30000.00
NURECA.NS cash_flow (annual, 2024-03-31) — End Cash Position: 140620000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -13030000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 282760000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: -37980000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -58680000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 0.00
NURECA.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 22100000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 22970000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 16150000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 74740000.00
NURECA.NS income_statement (annual, 2024-03-31) — Gross Profit: 308680000.00
NURECA.NS income_statement (annual, 2024-03-31) — Interest Expense: 3180000.00
NURECA.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 3180000.00
NURECA.NS income_statement (annual, 2024-03-31) — Interest Income: 38920000.00
NURECA.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 38920000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -14730000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 96940000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Inventory: 308510000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 1935940000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: 175760000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 0.00
NURECA.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 4300000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 14790000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 3260000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 18050000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 4300000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: 0.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 9760000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 47160000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -10000.00
NURECA.NS income_statement (annual, 2024-03-31) — Net Income: -17940000.00
NURECA.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: -17940000.00
NURECA.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: -17940000.00
NURECA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: -17940000.00
NURECA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: -17940000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: -25440000.00
NURECA.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: -17940000.00
NURECA.NS income_statement (annual, 2024-03-31) — Net Interest Income: 34030000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 89670000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 4010000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 4300000.00
NURECA.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: 34030000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: 10000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Net PPE: 50810000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -10860000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: -290000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 1908130000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 49020000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 9760000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 2920000.00
NURECA.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: -57120000.00
NURECA.NS income_statement (annual, 2024-03-31) — Normalized Income: -59179433.96
NURECA.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: -27120000.00
NURECA.NS income_statement (annual, 2024-03-31) — Operating Income: -125690000.00
NURECA.NS income_statement (annual, 2024-03-31) — Operating Revenue: 919280000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 10000175.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 2460000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 8800000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 1831110000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 22970000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: -33650000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 10000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 10000.00
NURECA.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 2590000.00
NURECA.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 156220000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Other Payable: 9900000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Other Properties: 48120000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 28780000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 1298310000.00
NURECA.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Payables: 61760000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 1680000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 131090000.00
NURECA.NS income_statement (annual, 2024-03-31) — Pretax Income: -25440000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
NURECA.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 1120000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -2015520000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -10860000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 25750000.00
NURECA.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 610600000.00
NURECA.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 23620000.00
NURECA.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 8490000.00
NURECA.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 8490000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -290000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 299260000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 856380000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 2105190000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 0.00
NURECA.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 101930000.00
NURECA.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 124030000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Share Issued: 10000175.00
NURECA.NS cash_flow (annual, 2024-03-31) — Short Term Debt Issuance: 0.00
NURECA.NS cash_flow (annual, 2024-03-31) — Short Term Debt Payments: -290000.00
NURECA.NS income_statement (annual, 2024-03-31) — Special Income Charges: 0.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 1931100000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 1908130000.00
NURECA.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 17240566.04
NURECA.NS income_statement (annual, 2024-03-31) — Tax Provision: -7500000.00
NURECA.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.29
NURECA.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 0.00
NURECA.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: 12490000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Total Assets: 2051650000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 1934360000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Total Debt: 25160000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 1931100000.00
NURECA.NS income_statement (annual, 2024-03-31) — Total Expenses: 1044970000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 120550000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 125730000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 27820000.00
NURECA.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 1710000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 8360000.00
NURECA.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 58480000.00
NURECA.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 58480000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Working Capital: 1833190000.00
NURECA.NS income_statement (annual, 2024-03-31) — Write Off: 0.00
NURECA.NS income_statement (quarterly, 2024-09-30) — +Operating Expense: 138900000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — +Total Revenue: 311890000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 94560000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 100170000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 63350000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Basic Average Shares: 10041667.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Basic EPS: -0.48
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 30640000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 100000000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 22350000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 1431900000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 100000000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 1943080000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 0.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Cost Of Revenue: 202760000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 1938240000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 9820000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 12740000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 22560000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 164950000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 1980000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Depreciation And Amortization In Income Statement: 6200000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Depreciation Income Statement: 6200000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 10041667.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Diluted EPS: -0.48
NURECA.NS income_statement (quarterly, 2024-09-30) — Diluted NI Availto Com Stockholders: -4820000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — EBIT: 1940000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — EBITDA: 8140000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 21390000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 72100000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Gross Profit: 109130000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Interest Expense: 2690000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Interest Expense Non Operating: 2690000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 276500000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 1965490000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 63350000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 20820000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 9670000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 30490000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 11030000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 60000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Net Income: -4820000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Net Income Common Stockholders: -4820000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Net Income Continuous Operations: -4820000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Net Income From Continuing And Discontinued Operation: -4820000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Net Income From Continuing Operation Net Minority Interest: -4820000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Net Income Including Noncontrolling Interests: -4820000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Net Interest Income: -2690000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Net Non Operating Interest Income Expense: -2690000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 72100000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 1921690000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 48500000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Normalized EBITDA: 8140000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Normalized Income: -4820000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Operating Income: -29770000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Operating Revenue: 311890000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 10000175.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 129670000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 30110000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 1843080000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Other Non Operating Income Expenses: 31710000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Other Operating Expenses: 96420000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 72100000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 1409550000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Payables: 109700000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Pretax Income: -750000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Reconciled Cost Of Revenue: 202760000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Reconciled Depreciation: 6200000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 10000175.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 1943080000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 1921690000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Tax Effect Of Unusual Items: 0.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Tax Provision: 4070000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Tax Rate For Calcs: 0.30
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 2149550000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 1952750000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 53050000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 1943080000.00
NURECA.NS income_statement (quarterly, 2024-09-30) — Total Expenses: 341660000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 206470000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 211310000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 41520000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 15140000.00
NURECA.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 1773290000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 144860000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 264630000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 10003571.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Basic EPS: -2.80
NURECA.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 165310000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 5400000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 5400000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 10003571.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: -2.80
NURECA.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: -28010000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — EBIT: -30770000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — EBITDA: -25370000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 99320000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 1750000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 1750000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Net Income: -28010000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: -28010000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: -28010000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Net Income Discontinuous Operations: 0.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -28010000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -28010000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: -28010000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -1750000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -1750000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: -25370000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Normalized Income: -28010000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Operating Income: -45540000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 264630000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 14770000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 101020000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Pretax Income: -32520000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 165310000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 5400000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Tax Provision: -4510000.00
NURECA.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.14
NURECA.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 310170000.00
NURECA.NS income_statement (annual, 2025-03-31) — +Operating Expense: 507870000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 120910000.00
NURECA.NS income_statement (annual, 2025-03-31) — +Total Revenue: 1096610000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 317400000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 65590000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 65590000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 33220000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 33220000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -31780000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -31780000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 987790000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 987790000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: 0.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: 0.00
NURECA.NS income_statement (annual, 2025-03-31) — Amortization: 3140000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 3140000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 35020000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 35020000.00
NURECA.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 10000175.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 9987854.00
NURECA.NS income_statement (annual, 2025-03-31) — Basic EPS: 0.85
NURECA.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 2.47
NURECA.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 140620000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 29950000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 29950000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -43230000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 25940000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 25940000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 100000000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 100000000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 32410000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 32410000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 1227320000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 1227320000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 0.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 0.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 32410000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 32410000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -90670000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -21110000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 9760000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Change In Payable: 14450000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -17070000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -104640000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -108130000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Common Stock: 100000000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 100000000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 1942840000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 1942840000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Common Stock Payments: 0.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 20080000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 20080000.00
NURECA.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 687020000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 189700000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Current Assets: 1899530000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 1899530000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 10510000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 10510000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Current Debt: 13250000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 13250000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 23760000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 23760000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Current Deferred Taxes Liabilities: 750000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Current Deferred Taxes Liabilities: 750000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 123990000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 123990000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 2300000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 2300000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Depreciation: 20240000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 23380000.00
NURECA.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 23380000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 5220000.00
NURECA.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 20240000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 5220000.00
NURECA.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 10000175.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 9987854.00
NURECA.NS income_statement (annual, 2025-03-31) — Diluted EPS: 0.85
NURECA.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 2.47
NURECA.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 8460000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 24670000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 120000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 120000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 0.00
NURECA.NS income_statement (annual, 2025-03-31) — EBIT: 17310000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — EBIT: 26710000.00
NURECA.NS income_statement (annual, 2025-03-31) — EBITDA: 40690000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — EBITDA: 31930000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: -80000.00
NURECA.NS cash_flow (annual, 2025-03-31) — End Cash Position: 32410000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -1690000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 354140000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 354140000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: -234060000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -45600000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -220000.00
NURECA.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 21700000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 19830000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 19830000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 33220000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 33220000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 121990000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 121990000.00
NURECA.NS income_statement (annual, 2025-03-31) — Gross Profit: 409590000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 127700000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 0.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 0.00
NURECA.NS income_statement (annual, 2025-03-31) — Interest Expense: 3880000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 6200000.00
NURECA.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 3880000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 6200000.00
NURECA.NS income_statement (annual, 2025-03-31) — Interest Income: 76220000.00
NURECA.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 76220000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -17820000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 76200000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Inventory: 399180000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 399180000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 1966560000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 1966560000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: 84390000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 35020000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 35020000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 20840000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 0.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 0.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 15430000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 15430000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 10470000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 10470000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 25900000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 25900000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 14410000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -1960000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 7020000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 7020000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 71960000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 71960000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 0.00
NURECA.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -590000.00
NURECA.NS income_statement (annual, 2025-03-31) — Net Income: 8460000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Net Income: 24670000.00
NURECA.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 8460000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 24670000.00
NURECA.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 8460000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 24670000.00
NURECA.NS income_statement (annual, 2025-03-31) — Net Income Discontinuous Operations: 0.00
NURECA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 8460000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 24670000.00
NURECA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 8460000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 24670000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 13430000.00
NURECA.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 8460000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 24670000.00
NURECA.NS income_statement (annual, 2025-03-31) — Net Interest Income: 64080000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -6200000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 51130000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 18880000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: 12450000.00
NURECA.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: 64080000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -6200000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Net PPE: 90210000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 90210000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -42940000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 6430000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 1923010000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 1923010000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 34750000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 34750000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 7020000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 7020000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 17260000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 17260000.00
NURECA.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 620000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 31930000.00
NURECA.NS income_statement (annual, 2025-03-31) — Normalized Income: -16781414.74
NURECA.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 24670000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: -190830000.00
NURECA.NS income_statement (annual, 2025-03-31) — Operating Income: -98280000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Operating Income: 6790000.00
NURECA.NS income_statement (annual, 2025-03-31) — Operating Revenue: 1096610000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 317400000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 10000175.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 10000175.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 2600000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 2600000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 9930000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 9930000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 1842850000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 1842850000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 19830000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 19830000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -64080000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 20080000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 20080000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 10000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 10000.00
NURECA.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 2370000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 19930000.00
NURECA.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 193030000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 72990000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Other Payable: 15290000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 15290000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Other Properties: 70130000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 70130000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 18140000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 18140000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 1194910000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 1194910000.00
NURECA.NS income_statement (annual, 2025-03-31) — Other Special Charges: -370000.00
NURECA.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Payables: 81000000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Payables: 81000000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2300000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2300000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 162080000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 162080000.00
NURECA.NS income_statement (annual, 2025-03-31) — Pretax Income: 13430000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 20510000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
NURECA.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 750000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -1311920000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -43230000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 45040000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 45040000.00
NURECA.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 687020000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 189700000.00
NURECA.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 23380000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 5220000.00
NURECA.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 14100000.00
NURECA.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 14100000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -1960000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Repurchase Of Capital Stock: 0.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 56990000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 56990000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 868200000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 868200000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 1363050000.00
NURECA.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 290000.00
NURECA.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 102590000.00
NURECA.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 124290000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Share Issued: 10000175.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 10000175.00
NURECA.NS cash_flow (annual, 2025-03-31) — Short Term Debt Issuance: 6430000.00
NURECA.NS income_statement (annual, 2025-03-31) — Special Income Charges: -130000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 1942840000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 1942840000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 1923010000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 1923010000.00
NURECA.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 14828585.26
NURECA.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
NURECA.NS income_statement (annual, 2025-03-31) — Tax Provision: 4970000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Tax Provision: -4160000.00
NURECA.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.37
NURECA.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.30
NURECA.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -13760000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Total Assets: 2099760000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 2099760000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 1953310000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 1953310000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Total Debt: 49660000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 49660000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 1942840000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 1942840000.00
NURECA.NS income_statement (annual, 2025-03-31) — Total Expenses: 1194890000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 310610000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 156920000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 156920000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 200230000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 200230000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 32930000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 32930000.00
NURECA.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 8260000.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 750000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 750000.00
NURECA.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 40070000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
NURECA.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 40070000.00
NURECA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
NURECA.NS balance_sheet (annual, 2025-03-31) — Working Capital: 1775540000.00
NURECA.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 1775540000.00
NURECA.NS income_statement (annual, 2025-03-31) — Write Off: 500000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 130910000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 341760000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 10037037.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 0.81
NURECA.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 221780000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 5320000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 5320000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 10037037.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.81
NURECA.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 8130000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — EBIT: 14790000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — EBITDA: 20110000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 119980000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 2480000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 2480000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Net Income: 8130000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 8130000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 8130000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Net Income Discontinuous Operations: 0.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 8130000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 8130000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 8130000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -2480000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -2480000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 20110000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 8130000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Operating Income: -10930000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 341760000.00
NURECA.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 25720000.00